Gilead signs a US$4.9 billion acquisition deal with Forty Seven
By Nikita Chaurasia  Date: 2020-03-03

Gilead signs a US$4.9 billion acquisition deal with Forty Seven

The deal would improve Gilead’s portfolio in Oncology and would allow the firm to conduct new First-in-Class oncology programs.

Gilead Sciences Inc., a U.S. based biotechnology company, has recently announced that it has inked a definitive agreement to acquire immuno-oncology company, Forty Seven Inc. for $4.9 billion. Reportedly, the transaction valued each share at $95.50 and was unanimously approved by the Boards of Directors of both the companies.

Reports cite that this acquisition deal could close by Q2 of 2020, subject to customary closing conditions and regulatory approvals. With this acquisition, Gilead’s immuno-oncology R&D portfolio would greatly benefit from the addition of Forty Seven’s lead drug candidate, magrolimab. 

Speaking on the move, Daniel O’Day, Chief Executive Officer and Chairman, Gilead Sciences, said that this deal would enhance Gilead’s presence in immuno-oncology and strengthen its portfolio as well as its clinical pipeline. Moreover, magrolimab would benefit its work in hematology, adding up a non-cell therapy initiative that accompanies Kite’s lineup of cell therapies developed for hematological cancers. 

Additionally, the biotech is looking forward to working with Forty Seven’s highly experienced team as it develops new treatments for some of the most complicated cancer forms, adds O’Day

Prior to this news, Gilead Sciences had made headlines when it revealed that it has appointed Sandra Horning, MD, in its Board of Directors. Reportedly, Dr. Horning had previously served as the Global Head of Product Development and Chief Medical Officer for Roche. 

Commenting on which, O’Day said that the company is delighted to welcome Sandra Horning in its Board of Directors and is looking forward to sharing her immense experience and vast industry expertise in drug development across numerous therapeutic sectors.

Additionally, Dr. Horning possesses the perspective of a leading physician who has invested over two decades in cancer treatment, that would come in handy while making strategic decisions for the company.

Source Credit: https://www.gilead.com/news-and-press/press-room/press-releases/2020/3/gilead-to-acquire-forty-seven-for-49-billion

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Coinbase puts forth a buyout offer for crypto brokerage firm Tagomi
Coinbase puts forth a buyout offer for crypto brokerage firm Tagomi
By Nikita Chaurasia

San Francisco based digital currency exchange major Coinbase has reportedly announced its acquisition of the crypto prime brokerage platform, Tagomi. For eight years, Coinbase has been known for its credibility in the field of industry-leading tradin...

National Congress of China recommends government-led blockchain fund
National Congress of China recommends government-led blockchain fund
By Nikita Chaurasia

The parliament of China, National People’s Congress, has reportedly given a suggestion for a blockchain development fund, backed by the government to be able to build up a good governance system. The most powerful and important political adviso...

Halifax to initiate COVID-19 vaccine trials with CanSino Biologics
Halifax to initiate COVID-19 vaccine trials with CanSino Biologics
By Nikita Chaurasia

The Dalhousie University, also known as Halifax University, located in Canada, has reportedly announced that its team would be working in collaboration with Chinese manufacturer, CanSino Biologics, to conduct the first-ever Canadian clinical trial fo...

Researchers to investigate the risk of airborne viruses in buildings
Researchers to investigate the risk of airborne viruses in buildings
By Nikita Chaurasia

As the world gradually paces back to normalcy after recuperating from the devastating effects of COVID-19, a research team from DOE’s Lawrence Berkeley National Laboratory (Berkeley Lab) embarked on the quest to study the risk of airborne virus...

NZME unveils a takeover bid of US$0.61 for its rival Stuff Limited
NZME unveils a takeover bid of US$0.61 for its rival Stuff Limited
By Nikita Chaurasia

NZME, a News Zealand media giant, has recently unveiled a symbolic US$0.61 (NZ$1) takeover bid for rival Stuff Limited in an attempt for consolidation of the news industry in the country, amid the downturn caused by the coronavirus pandemic. Nine Ent...